Pregabalin and gabapentin side effects differ

;

“Gabapentinoid” differences hidden in plain view

The exposition of this epidemiologic survey of “gabapentinoids,” by an elite research collaboration that includes groups at the University of Oxford and Sweden’s Karolinska Institute (Yasmina Molero and colleagues, British Medical Journal 365: 12147, 2019 (published online on June 12, 2019)), seems to have hidden in plain view what may prove critical differences … Read the rest

Methylphenidate bioavailability increased by alcohol

This four-way, unblinded, uncontrolled comparison by University of Michigan pharmacist H.J. Zhu and colleagues (from the University of South Carolina, Medical University of South Carolina, and the University of Tennessee) (H.J. Zhu and colleagues, Journal of Clinical Psycho- pharmacology 37(4): 419-428, 2017) regretably suffers from a lack of blindedness and placebo control that its torturously long discussion leaves unassuaged.

The … Read the rest

An opioid adjunct for treatment-resistant depression

Besides apprising us of the height at which FDA currently sets the bar for approval of new drugs in psychiatry, the recent approval of the s-enantiomer of ketamine for treatment-resistant depression provides grist for conjecture about what may be an increasing resemblance between criteria for approval of prescription drugs, which traditionally have required compelling evidence (before approval) of both safety … Read the rest

Ketamine for analgesia in renal colic

More recently discussed as a drug that induces a mood-state change devolving to a longer-term augmentive antidepressant effect in persons with erstwhile treatment-resistant depression, ketamine has analgesic effects for acute and chronic pain that have been documented plenteously over nearly two decades in both children and adults. A recent study by Iranian clinical researchers (A. Forouzan and colleages, Review of Read the rest

Confirmation bias and esketamine approval

This review, published on line by the FDA reviewers who voted (without unanimity) to approve esketamine for treatment-resistant depression (Jean Kim and colleagues, New England Journal of Medicine, published on line, ahead of print, on July 4, 2019), illustrates potential adversity that may devolve from confirmation bias with good intentions. We do not know whether the authors submitted it … Read the rest